Four out of every ten people with type 1 diabetes will develop chronic kidney disease — and until September 2026, there was no targeted therapy that could slow kidney decline beyond blood pressure and glucose control. That has now changed. Finerenone for type 1 diabetes received regulatory approval this month, making it the first new kidney-protective drug for T1D in over three decades. The medication, sold under the brand name Kerendia, is a non-steroidal mineralocorticoid receptor antagonist that research suggests can reduce the risk of kidney failure progression by approximately 18%. But not everyone with T1D qualifies — and the monitoring requirements are specific. Here is what you need to understand before your next appointment.

Table of Contents

1. What Is Finerenone? — A new class of kidney drug, explained in plain English
2. How Does Finerenone Protect the Kidneys in Type 1 Diabetes? — The mechanism that changed nephrology
3. What the Clinical Trials Revealed — FIDELIO-DKD and FIGARO-DKD data at a glance
4. Safety Profile, Side Effects & Dosage — What the trials say about risks
5. Who Should Take Finerenone — and Who Should Avoid It? — The candidacy checklist
6. Finerenone vs SGLT2 Inhibitors — Which kidney protection fits your situation?
7. How to Take Finerenone — Practical steps and common mistakes
8. Frequently Asked Questions — Snippet-ready answers to the most common queries

Finerenone for Type 1 Diabetes CKD: 7 Essential Facts (September 2026)

What Is Finerenone?

Four steps to safely start and monitor finerenone treatment.Finerenone (brand name Kerendia) is a non-steroidal mineralocorticoid receptor antagonist (MRA) — a once-daily oral tablet that blocks the damaging effects of the hormone aldosterone on the kidneys and heart. Unlike older MRAs such as spironolactone and eplerenone, finerenone’s non-steroidal structure gives it greater receptor selectivity and a lower risk of certain hormonal side effects.

To understand why finerenone for type 1 diabetes represents a genuine advance, you need to know what the mineralocorticoid receptor does. When aldosterone binds to MR receptors in kidney tissue, it triggers a cascade of inflammation and fibrosis — essentially, scarring inside the kidney’s delicate filtration units. In people with diabetes, this receptor is overactivated, even when blood pressure looks normal on paper.

Older drugs that block this receptor have existed for decades. Spironolactone, introduced in 1959, is an effective MRA but is steroidal — meaning it structurally resembles steroid hormones. This causes unwanted side effects including gynecomastia (breast tissue growth in men), menstrual irregularities, and sexual dysfunction. Eplerenone, approved in 2002, improved selectivity somewhat but is less potent and requires twice-daily dosing.

Finerenone solved both problems. Its non-steroidal structure means it does not cross-react with androgen or progesterone receptors, eliminating the hormonal side effects that limit spironolactone’s real-world use. It also distributes evenly between heart and kidney tissue, unlike eplerenone which concentrates primarily in the heart. This balanced tissue distribution is why finerenone for type 1 diabetes can simultaneously protect the kidneys and reduce cardiovascular risk.

The drug was first approved by the FDA in July 2021 for chronic kidney disease in type 2 diabetes. The September 2026 label expansion to include type 1 diabetes followed additional clinical review of the existing trial data and new analyses confirming that the pathophysiological rationale — MR overactivation in diabetic kidneys — applies regardless of diabetes type.

How Does Finerenone Protect the Kidneys in Type 1 Diabetes?

Think of your kidneys as a building’s plumbing system. High blood sugar and high pressure inside the glomeruli (the kidney’s microscopic filters) act like sustained water hammer — over years, they crack the pipes. What makes the damage worse is aldosterone. This hormone tells the kidney tissue to lay down scar tissue (fibrosis) and recruit inflammatory cells — the biological equivalent of slapping quick-dry cement over a leak instead of replacing the pipe.

Finerenone for type 1 diabetes interrupts this scarring process at its root. By blocking the mineralocorticoid receptor, it tells the kidney: “stop the fibrosis, stop the inflammation.” The result, based on clinical trial data, is slower eGFR decline and fewer patients progressing to end-stage kidney disease. Research suggests this anti-fibrotic effect operates independently of blood pressure reduction — meaning finerenone provides kidney protection through a pathway that ACE inhibitors and ARBs do not fully address.

An important detail for people considering finerenone for type 1 diabetes: the drug is designed to be added on top of existing standard-of-care therapy. In the trials, all participants were already taking maximum-tolerated doses of an ACE inhibitor or angiotensin receptor blocker (ARB). Finerenone does not replace these medications — it addresses the residual risk that remains after blood pressure and RAAS blockade are optimised.

The tissue-selectivity advantage matters here too. Unlike spironolactone, which concentrates more in the heart, finerenone distributes evenly between cardiac and renal tissue. This balanced profile explains why the trials showed simultaneous kidney and cardiovascular benefits — a dual protection that is particularly relevant for people with type 1 diabetes, who face elevated risks in both organ systems after decades of living with the condition.

What the Clinical Trials Revealed About Finerenone for Type 1 Diabetes

The evidence base supporting finerenone for type 1 diabetes draws primarily from the finerenone phase III programme, which enrolled over 13,000 patients across the FIDELIO-DKD and FIGARO-DKD trials. While these original trials studied type 2 diabetes populations, the consistency of the mechanism across diabetes types — combined with post-hoc analyses and real-world data — provided the foundation for the 2026 label expansion. Below is a summary of the key studies.

One caveat worth acknowledging: the direct randomised-controlled-trial evidence in type 1 diabetes specifically is more limited than the T2D dataset. The September 2026 approval reflects a regulatory judgment that the biological mechanism — overactive mineralocorticoid receptor signalling driving kidney fibrosis — operates the same way in T1D as T2D, and that the safety profile is likely comparable. Post-marketing surveillance studies in the T1D population are expected to report in 2027–2028.

What the numbers mean for you: An 18% relative risk reduction translates to roughly one kidney failure event prevented for every 29 patients treated over 2.6 years, based on the FIDELIO-DKD absolute risk data. These are not hypothetical statistics — they represent real people who avoided dialysis or transplantation. For a condition where the previous innovation was ACE inhibitors in the 1990s, this is a meaningful step forward.

Finerenone Safety Profile, Side Effects & Dosage

Every medication involves a benefit-risk calculation. The safety profile of finerenone for type 1 diabetes is well-characterised from the phase III programme, and the primary point of clinical attention is potassium. Here is what the data tells us, translated into practical terms.

The potassium story is the headline, but context matters. While 18.3% of finerenone-treated patients in FIDELIO-DKD developed potassium above 5.5 mmol/L, only 2.3% stopped the drug permanently because of it. The rate of serious hyperkalemia (≥6.0 mmol/L) was 4.3% on finerenone versus 2.3% on placebo. Most cases were manageable through dose adjustment, dietary counselling, or temporary interruption — not permanent discontinuation.

Factors that increase hyperkalemia risk include: baseline eGFR below 45, baseline potassium already in the upper-normal range (≥4.8 mmol/L), concomitant use of potassium-sparing diuretics or potassium supplements, and a diet very high in potassium-rich foods. Your doctor will assess these factors before starting finerenone for type 1 diabetes and will schedule regular blood tests — typically at week 4, week 8, week 12, and then every 4 months after dose stabilisation.

Standard starting dose: 10mg or 20mg once daily, determined by your baseline eGFR. If eGFR is ≥60, starting dose is typically 20mg. If eGFR is 25–59, starting dose is 10mg, with the option to titrate to 20mg after 4 weeks if potassium remains ≤4.8 mmol/L. The maximum dose is 20mg once daily, and you should take it at approximately the same time each day, with or without food.

Who Should Take Finerenone — and Who Should Avoid It?

The label for finerenone for type 1 diabetes is specific — and understanding the candidacy criteria helps you assess whether this drug is relevant to your situation before your next clinic visit.

If you are uncertain where you fall on this spectrum, your next step is straightforward: request a kidney function panel from your primary care doctor or endocrinologist. The two numbers that matter most are your eGFR and your urine albumin-to-creatinine ratio (UACR). These two values, combined with your current medication list and potassium level, determine whether finerenone for type 1 diabetes is an option worth discussing.

Finerenone vs SGLT2 Inhibitors and Other Kidney Protection Options

If you have been managing type 1 diabetes for years, you have likely heard of SGLT2 inhibitors — drugs like dapagliflozin and empagliflozin that were initially developed for glucose control but later showed impressive kidney and heart protection. So how does finerenone for type 1 diabetes compare?

The short answer: they work through completely different mechanisms, and they are not competitors — they are complementary tools. Research suggests that some patients may benefit from both, though this dual-therapy approach is still under study.

Which fits your situation? If elevated albuminuria is your primary kidney issue despite maximum ACEi/ARB therapy, the anti-fibrotic mechanism of finerenone may address the exact pathological process driving your disease. If your primary risk is cardiovascular — and you can manage the DKA monitoring protocols required for SGLT2 inhibitor use in T1D — an SGLT2 inhibitor may offer broader CV protection. For many patients, the eventual answer may be both: the CONFIDENCE trial (expected to report in 2027) is specifically studying finerenone plus an SGLT2 inhibitor in CKD populations.

You might also need to manage your blood pressure alongside kidney protection. If you want to understand the range of options available, blood pressure medications at MedsBase include several classes that may complement your kidney-protection strategy.

How to Take Finerenone — Practical Guidance

Starting any new chronic medication involves logistics. Here is a practical, step-by-step approach to finerenone for type 1 diabetes, based on the clinical trial protocols and the prescribing information.

Before Starting: The Baseline Check

1. Request baseline labs. Your doctor needs serum potassium, eGFR, and UACR within 4 weeks of starting. If potassium is >5.0 mmol/L, the drug cannot be started.
2. Review your medication list. Identify any strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir, certain HIV protease inhibitors), moderate CYP3A4 inhibitors (erythromycin, fluconazole, verapamil), and grapefruit juice consumption. Grapefruit is a moderate CYP3A4 inhibitor — your doctor may advise limiting intake.
3. Confirm your ACEi or ARB dose is maximised. Finerenone is designed as add-on therapy. If you are not yet on an ACEi/ARB, that step should come first.

Starting and Titrating

4. Start at 10mg or 20mg once daily. If eGFR ≥60, start at 20mg. If eGFR 25–59, start at 10mg. Take at the same time each day — morning is typical, but consistency matters more than timing.
5. Return for a potassium check at week 4. This is non-negotiable. If potassium is ≤4.8, you may titrate from 10mg to 20mg (if you started on 10mg). If potassium is 4.9–5.5, stay at the current dose. If >5.5, pause finerenone and recheck — your doctor may restart at a lower dose once potassium normalises.
6. Recheck potassium at weeks 8 and 12. After dose stabilisation, monitoring extends to every 4 months.
7. Watch for an initial eGFR dip. A small decline in the first 4 weeks (typically 2-4 mL/min/1.73 m²) is expected and was associated with BETTER long-term kidney outcomes in the trials. Do not panic and do not stop — confirm the pattern with your doctor.

Common Mistakes to Avoid

• Skipping the 4-week potassium check. Hyperkalemia risk peaks in the first month. Missing this blood test is the single most preventable cause of treatment interruption.
• Adding a potassium supplement without discussion. Some people with diabetes take potassium supplements for other reasons. Combining these with finerenone increases hyperkalemia risk.
• Stopping because of the initial eGFR dip. This haemodynamic effect is a sign the drug is working — the glomerular pressure reduction that accompanies MR blockade causes a small, reversible eGFR decline that stabilises and is associated with slower long-term decline.
• Taking finerenone on an empty adrenal axis. If you are being treated for adrenal insufficiency, you need careful endocrinology input — the drug’s mechanism involves the same hormonal pathways.
• Using NSAIDs regularly without discussion. Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac) can reduce kidney perfusion and increase hyperkalemia risk when combined with MRAs. Discuss with your doctor if you use NSAIDs frequently.

If you are managing diabetes alongside other chronic conditions, you may find it helpful to review the range of medications available for diabetes management. Browse diabetes medications at MedsBase to understand your options — always discuss any medication changes with your healthcare provider first.

Frequently Asked Questions About Finerenone for Type 1 Diabetes

The Bottom Line

Finerenone for type 1 diabetes represents the first genuinely new mechanism for kidney protection in the T1D population since the introduction of ACE inhibitors more than 30 years ago. By targeting the mineralocorticoid receptor — the biological switch that drives fibrosis and inflammation inside kidney tissue — it addresses residual risk that blood pressure control and glucose management alone cannot eliminate.

The evidence is clear but comes with important nuance. The landmark trials (FIDELIO-DKD and FIGARO-DKD) demonstrated an 18% reduction in kidney failure risk and a 13% reduction in cardiovascular events — but these studies were conducted in type 2 diabetes populations. The 2026 label expansion to T1D is based on the mechanistic rationale that MR overactivation is a shared pathological feature across diabetes types, not on a dedicated T1D randomised trial. This does not mean finerenone will not work for you — the biology is sound — but it does mean that post-marketing surveillance data, expected in 2027–2028, will add important context to the safety and efficacy picture in the T1D population specifically.

Your immediate action step: If you have type 1 diabetes and know or suspect you have kidney involvement, request a kidney function panel (eGFR, UACR, serum potassium) from your doctor. These three numbers determine whether finerenone for type 1 diabetes is an option. If your eGFR is ≥25, your UACR shows elevated albuminuria, and your potassium is ≤4.8 — and you are already on an ACEi or ARB — you may be a candidate. Bring the candidacy criteria from this article to your next appointment.

Two questions worth asking next: If you are managing multiple chronic conditions, understanding how kidney health intersects with cardiovascular risk may be your next priority — blood pressure medications at MedsBase provides an overview of the RAAS-blocking drugs that form the foundation of kidney protection. And if you have been diagnosed with diabetes-related kidney changes, understanding the full spectrum of diabetes medications available — from glucose control to organ protection — can help you have a more informed conversation with your healthcare team.

Living with type 1 diabetes for decades is a marathon that demands adaptation at every stage. Finerenone for type 1 diabetes is not a cure — no single pill is. But for people whose kidney function is declining despite doing everything else right, it is a tool worth understanding, and worth asking about.